AQST vs. ADPT, SNDX, SYRE, SPRY, NRIX, ELVN, NTLA, BGM, RCUS, and VIR
Should you be buying Aquestive Therapeutics stock or one of its competitors? The main competitors of Aquestive Therapeutics include Adaptive Biotechnologies (ADPT), Syndax Pharmaceuticals (SNDX), Spyre Therapeutics (SYRE), ARS Pharmaceuticals (SPRY), Nurix Therapeutics (NRIX), Enliven Therapeutics (ELVN), Intellia Therapeutics (NTLA), Qilian International Holding Group (BGM), Arcus Biosciences (RCUS), and Vir Biotechnology (VIR). These companies are all part of the "pharmaceutical products" industry.
Aquestive Therapeutics vs.
Aquestive Therapeutics (NASDAQ:AQST) and Adaptive Biotechnologies (NASDAQ:ADPT) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, risk, profitability, dividends, analyst recommendations, valuation, institutional ownership, community ranking and media sentiment.
Aquestive Therapeutics received 117 more outperform votes than Adaptive Biotechnologies when rated by MarketBeat users. Likewise, 68.25% of users gave Aquestive Therapeutics an outperform vote while only 57.99% of users gave Adaptive Biotechnologies an outperform vote.
32.5% of Aquestive Therapeutics shares are held by institutional investors. Comparatively, 99.2% of Adaptive Biotechnologies shares are held by institutional investors. 7.9% of Aquestive Therapeutics shares are held by company insiders. Comparatively, 6.2% of Adaptive Biotechnologies shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
Aquestive Therapeutics has a net margin of -59.75% compared to Adaptive Biotechnologies' net margin of -89.12%. Aquestive Therapeutics' return on equity of 0.00% beat Adaptive Biotechnologies' return on equity.
Aquestive Therapeutics has higher earnings, but lower revenue than Adaptive Biotechnologies. Adaptive Biotechnologies is trading at a lower price-to-earnings ratio than Aquestive Therapeutics, indicating that it is currently the more affordable of the two stocks.
Aquestive Therapeutics has a beta of 2.76, indicating that its stock price is 176% more volatile than the S&P 500. Comparatively, Adaptive Biotechnologies has a beta of 1.53, indicating that its stock price is 53% more volatile than the S&P 500.
In the previous week, Adaptive Biotechnologies had 11 more articles in the media than Aquestive Therapeutics. MarketBeat recorded 15 mentions for Adaptive Biotechnologies and 4 mentions for Aquestive Therapeutics. Aquestive Therapeutics' average media sentiment score of 1.38 beat Adaptive Biotechnologies' score of 0.59 indicating that Aquestive Therapeutics is being referred to more favorably in the media.
Aquestive Therapeutics currently has a consensus price target of $10.57, indicating a potential upside of 229.33%. Adaptive Biotechnologies has a consensus price target of $9.40, indicating a potential upside of 14.36%. Given Aquestive Therapeutics' stronger consensus rating and higher possible upside, research analysts plainly believe Aquestive Therapeutics is more favorable than Adaptive Biotechnologies.
Summary
Aquestive Therapeutics beats Adaptive Biotechnologies on 14 of the 19 factors compared between the two stocks.
Get Aquestive Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for AQST and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Aquestive Therapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:AQST) was last updated on 3/28/2025 by MarketBeat.com Staff
